Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$74.1 million.

  • Relay Therapeutics' Profit After Tax rose 1584.02% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$297.6 million, marking a year-over-year increase of 1379.09%. This contributed to the annual value of -$337.7 million for FY2024, which is 124.72% up from last year.
  • As of Q3 2025, Relay Therapeutics' Profit After Tax stood at -$74.1 million, which was up 1584.02% from -$70.4 million recorded in Q2 2025.
  • Relay Therapeutics' 5-year Profit After Tax high stood at -$42.2 million for Q1 2021, and its period low was -$193.4 million during Q2 2021.
  • Over the past 5 years, Relay Therapeutics' median Profit After Tax value was -$76.8 million (recorded in 2022), while the average stood at -$81.9 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 62369.03% in 2021, then soared by 6029.56% in 2022.
  • Quarter analysis of 5 years shows Relay Therapeutics' Profit After Tax stood at -$67.5 million in 2021, then fell by 0.07% to -$67.5 million in 2022, then dropped by 23.69% to -$83.5 million in 2023, then increased by 8.97% to -$76.0 million in 2024, then rose by 2.44% to -$74.1 million in 2025.
  • Its last three reported values are -$74.1 million in Q3 2025, -$70.4 million for Q2 2025, and -$77.1 million during Q1 2025.